You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Towards the end of 2012, a 20-partner strong project was launched to enhance understanding of how potential drugs interact with their targets. The aim of the Kinetics for Drug Discovery (K4DD) project is to provide a set of tools, methods and models that enable scientists and drug designers to reliably predict a molecule's kinetic properties (its "kinotype"). Such knowledge and expertise will ease decision-making in drug discovery, and could ultimately improve timelines, the use of resources, and the success rate.
TI Pharma is the program manager for this project and coordinates stakeholder interaction. We also provide the infrastructure to support daily operations, including communications, and the development of a training program for the K4DD fellows.
For more information and a complete list of participating organizations, please visit K4DD's website.
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board